Audeo Oncology (Audeo Oncology) Debt-to-Asset : 0.00 (As of Sep. 2012)

View and export this data going back to . Start your Free Trial

What is Audeo Oncology Debt-to-Asset?

Audeo Oncology's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2012 was $0.00 Mil. Audeo Oncology's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2012 was $0.00 Mil. Audeo Oncology's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Sep. 2012 was $7.81 Mil. Audeo Oncology's debt to asset for the quarter that ended in Sep. 2012 was 0.00.

Audeo Oncology Debt-to-Asset Historical Data

The historical data trend for Audeo Oncology's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Audeo Oncology Debt-to-Asset Chart

Audeo Oncology Annual Data

Trend

Jun10

Jun11

Jun12

Debt-to-Asset

Audeo Oncology Quarterly Data
	Jun11	Mar12	Jun12	Sep12
Debt-to-Asset	-	-	-	-

Competitive Comparison of Audeo Oncology's Debt-to-Asset

For the Drug Manufacturers - General subindustry, Audeo Oncology's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Audeo Oncology's Debt-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Audeo Oncology's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Audeo Oncology's Debt-to-Asset falls into.

Audeo Oncology Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Audeo Oncology's Debt-to-Asset for the fiscal year that ended in Jun. 2012 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	0)	/	9.712
	=	0.00

Audeo Oncology's Debt-to-Asset for the quarter that ended in Sep. 2012 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	0)	/	7.805
	=	0.00

Audeo Oncology (DELISTED:AURX) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Audeo Oncology Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Audeo Oncology's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Audeo Oncology (Audeo Oncology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Audeo Oncology Inc (DELISTED:AURX) » Definitions » Debt-to-Asset

Traded in Other Exchanges

N/A

Address

Website

http://www.audeooncology.com

Audeo Oncology, Inc was incorporated in Delaware in June 2012. It is a late stage biopharmaceutical company utilizing its Hyaluronic Acid Chemotransport Technology, or HyACT, to target cancer drugs preferentially to tumor cells to enhance drug activity. HyACT is a flexible platform technology designed to increase the effectiveness of anti-cancer agents without increasing treatment toxicity. It seeks to reduce the risks related to drug development by using known anti-cancer drugs, and aim to enhance their commercial value by improving their effectiveness. The Company's lead HyACT product candidate, HA-Irinotecan, is currently in a pivotal Phase III clinical trial for metastatic colorectal cancer, or mCRC. HA-Irinotecan is also in an investigator-sponsored Phase II clinical trial for small cell lung cancer, or SCLC. It also has two other HyACT product candidates that have successfully completed Phase I clinical trials. In addition to its current clinical-stage product candidates, it aims to develop a pipeline of product candidates by exploiting its significant know-how in cancer stem cell biology and cancer metabolism combined with the Versatile Assembly on Stable Templates, or VAST, molecule drug discovery technology that it will in-license. The Company's lead product candidate is HyACT-targeted irinotecan, or HA-Irinotecan, for the treatment of mCRC. Irinotecan, which is marketed in major markets by Pfizer as Camptosar, is an off-patent chemotherapy drug widely used in the treatment of mCRC. Government authorities in the United States (including federal, state and local authorities) and in other countries extensively regulate the manufacture, research, clinical development, labeling, packaging, distribution, post-approval monitoring and reporting, advertising, promotion, export and import of pharmaceutical products, such as those it is developing.